As I said, we support the idea of all Canadians having access to the necessary medication. I think that is very important. As most people on the panel have said, it clearly does lead to savings elsewhere in the system. Again, our sector provides headroom for that so that new medications can be afforded.
I would make one comment on it, because there have been a few questions about quality and safety. The way drugs are approved in Canada is the same as the way they are approved in the United States by the Food and Drug Administration, and in Europe by the European Medicines Agency. Generic medicines are subject to the same standards. This is internationally accepted science.
After patents, our role is to provide protection for the new innovative medicines, which are often very expensive. Even the PMPRB has acknowledged that it hasn't always done a terrific job in controlling prices in Canada.
After the patents expire, you have good-quality medicines. The science is there. They should be used to help broaden access to medicines for all Canadians.